On Friday 24th March, Neuro-Bio was mentioned in the Health Investor UK. The article talked about the current series C fundraise and the previous ones, quoting a message from CEO, Susan Greenfield : “It’s time we had a paradigm shift in AD. It’s time...
We are pleased to share the article from Mensa, the magazine which subscribers must have scored in the top 2 percent IQ of the general population to have access. Neuro-Bio’s CEO, Susan Greenfield was described as a brilliant mind. Click here to read the full...
On Wednesday 8th March, Neuro-Bio’s CEO, Susan Greenfield, will be talking at the “In-Person Networking Event” for Global Woman & co. in occasion of the International Women’s Day. More information can be found by clicking the...
As 2022 draws to a close, it seems a good moment to share with you the progress made over the last 12 months. In the Spring (April 5th) and in the Autumn (Sept 27th) we were delighted to host two events for all those external individuals and organisations who have...
Neuro-Bio has been mentioned as Global Alzheimer’s Disease Diagnostic Market Key Player by Maximize market research pvt. ltd. To read the full article, click the link.
Neuro-Bio was mentioned on 2 articles on August the 27th on Mergermarket, an ACURIS company. Please find here the full article on Neuro-Bio’s fundraising plans: Neuro-Bio seeks to raise GBP 10m Series C by 1H22 for Alzheimer’s peptide drug – CEO _ Mergermarket And...
